Sana Biotechnology Files 8-K on Operations and Other Events

Ticker: SANA · Form: 8-K · Filed: 2025-08-06T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-condition, corporate-events

TL;DR

Sana Bio dropped an 8-K on ops & other stuff. Check it.

AI Summary

On August 6, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing indicates the company is providing information regarding its results of operations and financial condition, as well as other events. Specific details on financial performance or the nature of the 'other events' are not elaborated in this summary.

Why It Matters

This filing signals that Sana Biotechnology is disclosing important updates regarding its financial health and potentially significant corporate activities to the public.

Risk Assessment

Risk Level: medium — An 8-K filing can contain material information, but without specific details on the 'other events' or financial condition, the immediate risk impact is uncertain.

Key Players & Entities

Sana Biotechnology, Inc. (company) — Registrant
August 6, 2025 (date) — Date of earliest event reported
Delaware (jurisdiction) — State of incorporation
001-39941 (identifier) — Commission File Number
188 East Blaine Street, Suite 400 (address) — Principal executive offices
Seattle, Washington 98102 (address) — Principal executive offices
(206) 701-7914 (phone_number) — Registrant's telephone number

FAQ

What specific 'Results of Operations and Financial Condition' are being reported by Sana Biotechnology?

The provided text does not detail the specific results of operations or financial condition, only that this item is being reported.

What are the 'Other Events' that Sana Biotechnology is reporting on August 6, 2025?

The filing indicates 'Other Events' are being reported, but the nature of these events is not specified in the provided text.

When was Sana Biotechnology incorporated, and in which jurisdiction?

Sana Biotechnology, Inc. was incorporated in Delaware.

What is Sana Biotechnology's principal executive office address?

Sana Biotechnology's principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.

What is the Commission File Number for Sana Biotechnology?

Sana Biotechnology's Commission File Number is 001-39941.

From the Filing

0001193125-25-174506.txt : 20250806 0001193125-25-174506.hdr.sgml : 20250806 20250806163130 ACCESSION NUMBER: 0001193125-25-174506 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc. CENTRAL INDEX KEY: 0001770121 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39941 FILM NUMBER: 251190157 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 701-7914 MAIL ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 d36055d8k.htm 8-K 8-K false 0001770121 0001770121 2025-08-06 2025-08-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025     SANA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter)       Delaware   001-39941   83-1381173 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number) 188 East Blaine Street , Suite 400 Seattle , Washington 98102 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (206) 701-7914     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   SANA   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 2.02 Results of Operations and Financial Condition. The information set forth in Item 8.01 under the caption “Certain Preliminary Financial Information (Unaudited)” is incorporated into this Item 2.02 by reference.   Item 8.01 Other Events. Certain Preliminary Financial Information (Unaudited) Sana Biotechnology, Inc. (the “Company”) reports that it estimates its cash, cash equivalents, and marketable securities as of July 31, 2025 were approximately $90.1 million. Additionally, as a result of changes in the Company’s business plans and intention to pursue potential subleases for the Company’s Bothell, Washington and Seattle, Washington